Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Testagen
Also known as: Lys-Glu-Asp-Gly, KEDG
Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator series, marketed as a testicular bioregulator for testosterone support. It is one of the least evidence-backed peptides in the bioregulator system, with claims based primarily on theoretical extrapolation from the bioregulator paradigm rather than direct endocrine studies.
Risk Level
Medium RiskDifficulty
Intermediate| Molecular Formula | C16H27N4O9 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in Leydig cells and testicular tissue, theoretically normalizing testosterone synthesis. The mechanism is entirely hypothetical, based on the general Khavinson theory of peptide-DNA complementary binding rather than demonstrated endocrine pharmacology.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 10-30 days. No established dosing from clinical trials. Often marketed in combination with other bioregulators. Repeat courses every 3-6 months as per general bioregulator protocol.
Side Effects & Risks
No safety data available. Theoretical endocrine disruption risk given the claimed mechanism. The lack of evidence for efficacy means the risk-benefit profile is essentially uncharacterizable. Rapid degradation of the tetrapeptide likely limits systemic effects.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.